ACIU
AC Immune SA
Price Chart
Latest Quote
$3.27
Current Price| Previous Close | $3.19 |
| Open | $3.19 |
| Day High | $3.35 |
| Day Low | $3.19 |
| Volume | 147,549 |
Stock Information
Note: Financial values converted from CHF to USD
| Shares Outstanding | 100.60M |
| Total Debt | $5.99M |
| Cash Equivalents | $139.37M |
| Revenue | $5.62M |
| Net Income | $-92.35M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $328.96M |
| EPS (TTM) | $-0.94 |
| Exchange | NGM |
📊 Custom Metrics & Score
Score: 17/42| Debt to Equity | 0.05 |
| Debt to Earnings | -0.11 |
| Current Ratio | 1.71 |
| Quick Ratio | 1.66 |
| Profit Margin | -186.44% |
| Return on Equity | -45.35% |
| Avg FCF Growth | -48.88% |
| FCF Yield | 19.84% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $3.27 | 147,549 |
| 2026-01-30 | $3.19 | 250,700 |
| 2026-01-29 | $3.40 | 169,800 |
| 2026-01-28 | $3.47 | 256,100 |
| 2026-01-27 | $3.54 | 254,000 |
| 2026-01-26 | $3.48 | 222,700 |
| 2026-01-23 | $3.70 | 573,700 |
| 2026-01-22 | $3.63 | 423,800 |
| 2026-01-21 | $3.40 | 268,200 |
| 2026-01-20 | $3.32 | 485,900 |
| 2026-01-16 | $3.51 | 198,400 |
| 2026-01-15 | $3.63 | 387,500 |
| 2026-01-14 | $3.67 | 506,900 |
| 2026-01-13 | $3.70 | 456,400 |
| 2026-01-12 | $3.52 | 323,100 |
| 2026-01-09 | $3.41 | 362,500 |
| 2026-01-08 | $3.44 | 244,300 |
| 2026-01-07 | $3.68 | 471,200 |
| 2026-01-06 | $3.43 | 970,600 |
| 2026-01-05 | $3.52 | 1,086,300 |
About AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
📰 Latest News
Top Penny Stocks To Watch In January 2026
Simply Wall St. • 2026-01-13T18:05:47Z
Retail investors are AC Immune SA's (NASDAQ:ACIU) biggest owners and were rewarded after market cap rose by US$53m last week
Simply Wall St. • 2026-01-08T12:47:09Z
Startup Lifordi Seeks to Deliver Potent Medication for Autoimmune Diseases
The Wall Street Journal • 2025-12-26T15:00:00Z
Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks
Simply Wall St. • 2025-12-12T12:04:53Z
AC Immune posts positive data for Parkinson’s immunotherapy
BioPharma Dive • 2025-12-11T13:36:00Z
Here's Why We're Watching AC Immune's (NASDAQ:ACIU) Cash Burn Situation
Simply Wall St. • 2025-12-05T11:08:20Z
AC Immune (ACIU): Losses Narrow 5.9% Annually; Revenue Growth Forecast at 55.6% Pre-Earnings
Simply Wall St. • 2025-11-05T03:22:20Z
AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates
Zacks • 2025-11-04T13:55:01Z
AC Immune: Q3 Earnings Snapshot
Associated Press Finance • 2025-11-04T12:48:39ZAC Immune And 2 Other Promising Penny Stocks
Simply Wall St. • 2025-10-31T12:05:17Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $27,309,000 | $14,801,000 | $3,935,000 | $0 |
| Operating Revenue | $27,309,000 | $14,801,000 | $3,935,000 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $133,000 | $176,000 | $355,000 | $581,000 |
| Total Expenses | $79,687,000 | $68,425,000 | $74,782,000 | $79,010,000 |
| Other Income Expense | $-1,598,000 | $-1,467,000 | $393,000 | $113,000 |
| Net Non Operating Interest Income Expense | $3,063,000 | $868,000 | $-286,000 | $5,904,000 |
| Interest Expense Non Operating | $133,000 | $176,000 | $355,000 | $581,000 |
| Operating Expense | $79,687,000 | $68,425,000 | $74,782,000 | $79,010,000 |
| Other Operating Expenses | $5,683,000 | $3,243,000 | $4,864,000 | $5,849,000 |
| General And Administrative Expense | $11,434,000 | $10,576,000 | $9,582,000 | $10,879,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-50,916,000 | $-54,233,000 | $-70,753,000 | $-72,996,000 |
| Net Interest Income | $3,063,000 | $868,000 | $-286,000 | $5,904,000 |
| Interest Income | $3,196,000 | $1,044,000 | $69,000 | $6,485,000 |
| Normalized Income | $-49,453,830 | $-52,890,695 | $-71,094,910 | $-73,105,610 |
| Net Income From Continuing And Discontinued Operation | $-50,916,000 | $-54,233,000 | $-70,753,000 | $-72,996,000 |
| Total Operating Income As Reported | $-52,378,000 | $-53,624,000 | $-70,847,000 | $-79,010,000 |
| Net Income Common Stockholders | $-50,916,000 | $-54,233,000 | $-70,753,000 | $-72,996,000 |
| Net Income | $-50,916,000 | $-54,233,000 | $-70,753,000 | $-72,996,000 |
| Net Income Including Noncontrolling Interests | $-50,916,000 | $-54,233,000 | $-70,753,000 | $-72,996,000 |
| Net Income Continuous Operations | $-50,916,000 | $-54,233,000 | $-70,753,000 | $-72,996,000 |
| Pretax Income | $-50,913,000 | $-54,223,000 | $-70,740,000 | $-72,993,000 |
| Interest Income Non Operating | $3,196,000 | $1,044,000 | $69,000 | $6,485,000 |
| Operating Income | $-52,378,000 | $-53,624,000 | $-70,847,000 | $-79,010,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.51 | $-0.64 | $-0.85 | $-0.97 |
| Basic EPS | $-0.51 | $-0.64 | $-0.85 | $-0.97 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-135,830 | $-124,695 | $51,090 | $3,390 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-47,020,000 | $-50,365,000 | $-68,419,000 | $-70,119,000 |
| Total Unusual Items | $-1,598,000 | $-1,467,000 | $393,000 | $113,000 |
| Total Unusual Items Excluding Goodwill | $-1,598,000 | $-1,467,000 | $393,000 | $113,000 |
| Reconciled Depreciation | $2,162,000 | $2,215,000 | $2,359,000 | $2,406,000 |
| EBITDA (Bullshit earnings) | $-48,618,000 | $-51,832,000 | $-68,026,000 | $-70,006,000 |
| EBIT | $-50,780,000 | $-54,047,000 | $-70,385,000 | $-72,412,000 |
| Diluted Average Shares | $99,691,971 | $84,694,616 | $83,554,412 | $74,951,833 |
| Basic Average Shares | $99,691,971 | $84,694,616 | $83,554,412 | $74,951,833 |
| Diluted NI Availto Com Stockholders | $-50,916,000 | $-54,233,000 | $-70,753,000 | $-72,996,000 |
| Tax Provision | $3,000 | $10,000 | $13,000 | $3,000 |
| Gain On Sale Of Security | $-1,598,000 | $-1,467,000 | $393,000 | $113,000 |
| Research And Development | $62,570,000 | $54,606,000 | $60,336,000 | $62,282,000 |
| Selling General And Administration | $11,434,000 | $10,576,000 | $9,582,000 | $10,879,000 |
| Salaries And Wages | $11,434,000 | $10,576,000 | $9,582,000 | $10,879,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $61,854,000 | $110,227,000 | $118,575,000 | $181,563,000 |
| Total Assets | $230,913,000 | $182,814,000 | $185,938,000 | $261,443,000 |
| Total Non Current Assets | $58,919,000 | $57,661,000 | $57,844,000 | $58,809,000 |
| Investmentin Financial Assets | $415,000 | $361,000 | $361,000 | $363,000 |
| Goodwill And Other Intangible Assets | $50,416,000 | $50,416,000 | $50,416,000 | $50,416,000 |
| Other Intangible Assets | $50,416,000 | $50,416,000 | $50,416,000 | $50,416,000 |
| Current Assets | $171,994,000 | $125,153,000 | $128,094,000 | $202,634,000 |
| Prepaid Assets | $4,302,000 | $6,437,000 | $4,708,000 | $3,015,000 |
| Receivables | $2,203,000 | $15,668,000 | $800,000 | $1,403,000 |
| Other Receivables | $1,243,000 | $291,000 | $532,000 | $1,076,000 |
| Taxes Receivable | $960,000 | $577,000 | $268,000 | $327,000 |
| Accounts Receivable | $0 | $14,800,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $165,489,000 | $103,048,000 | $122,586,000 | $198,216,000 |
| Cash And Cash Equivalents | $36,275,000 | $78,494,000 | $31,586,000 | $82,216,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $5,427,000 | $3,497,000 | $2,801,000 | $2,910,000 |
| Long Term Debt And Capital Lease Obligation | $4,401,000 | $2,825,000 | $2,253,000 | $2,340,000 |
| Current Debt And Capital Lease Obligation | $1,026,000 | $672,000 | $548,000 | $570,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $118,643,000 | $22,171,000 | $16,947,000 | $29,464,000 |
| Total Non Current Liabilities Net Minority Interest | $17,805,000 | $8,595,000 | $5,466,000 | $9,438,000 |
| Non Current Deferred Liabilities | $4,560,000 | $0 | - | - |
| Current Liabilities | $100,838,000 | $13,576,000 | $11,481,000 | $20,026,000 |
| Current Deferred Liabilities | $85,056,000 | $138,000 | $587,000 | $717,000 |
| Payables And Accrued Expenses | $14,756,000 | $12,766,000 | $10,346,000 | $18,739,000 |
| Payables | $2,658,000 | $1,679,000 | $929,000 | $2,003,000 |
| Accounts Payable | $2,658,000 | $1,679,000 | $929,000 | $2,003,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $112,270,000 | $160,643,000 | $168,991,000 | $231,979,000 |
| Total Equity Gross Minority Interest | $112,270,000 | $160,643,000 | $168,991,000 | $231,979,000 |
| Stockholders Equity | $112,270,000 | $160,643,000 | $168,991,000 | $231,979,000 |
| Gains Losses Not Affecting Retained Earnings | $-5,000 | $-51,000 | $10,000 | $0 |
| Retained Earnings | $-368,239,000 | $-316,197,000 | $-264,015,000 | $-200,942,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $10,899,773 | $5,243,958 | $6,214,021 | $6,221,617 |
| Ordinary Shares Number | $100,410,377 | $99,197,829 | $83,620,364 | $83,479,013 |
| Share Issued | $111,310,150 | $104,441,787 | $89,834,385 | $89,700,630 |
| Tangible Book Value | $61,854,000 | $110,227,000 | $118,575,000 | $181,563,000 |
| Invested Capital | $112,270,000 | $160,643,000 | $168,991,000 | $231,979,000 |
| Working Capital | $71,156,000 | $111,577,000 | $116,613,000 | $182,608,000 |
| Capital Lease Obligations | $5,427,000 | $3,497,000 | $2,801,000 | $2,910,000 |
| Total Capitalization | $112,270,000 | $160,643,000 | $168,991,000 | $231,979,000 |
| Foreign Currency Translation Adjustments | $-5,000 | $-51,000 | $10,000 | $0 |
| Treasury Stock | $218,000 | $105,000 | $124,000 | $124,000 |
| Additional Paid In Capital | $478,506,000 | $474,907,000 | $431,323,000 | $431,251,000 |
| Capital Stock | $2,226,000 | $2,089,000 | $1,797,000 | $1,794,000 |
| Common Stock | $2,226,000 | $2,089,000 | $1,797,000 | $1,794,000 |
| Employee Benefits | $8,844,000 | $5,770,000 | $3,213,000 | $7,098,000 |
| Non Current Deferred Revenue | $4,560,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $4,401,000 | $2,825,000 | $2,253,000 | $2,340,000 |
| Current Deferred Revenue | $85,056,000 | $138,000 | $587,000 | $717,000 |
| Current Capital Lease Obligation | $1,026,000 | $672,000 | $548,000 | $570,000 |
| Current Accrued Expenses | $12,098,000 | $11,087,000 | $9,417,000 | $16,736,000 |
| Investments And Advances | $415,000 | $361,000 | $361,000 | $363,000 |
| Net PPE | $8,088,000 | $6,884,000 | $7,067,000 | $8,030,000 |
| Accumulated Depreciation | $-12,468,000 | $-10,996,000 | $-9,343,000 | $-7,550,000 |
| Gross PPE | $20,556,000 | $17,880,000 | $16,410,000 | $15,580,000 |
| Leases | $1,863,000 | $1,662,000 | $1,640,000 | $810,000 |
| Construction In Progress | $0 | $0 | $3,000 | $695,000 |
| Other Properties | $10,536,000 | $10,233,000 | $9,765,000 | $9,142,000 |
| Machinery Furniture Equipment | $2,837,000 | $2,539,000 | $2,294,000 | $2,157,000 |
| Buildings And Improvements | $5,320,000 | $3,446,000 | $2,708,000 | $2,776,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $129,214,000 | $24,554,000 | $91,000,000 | $116,000,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $65,266,000 | $-61,209,000 | $-74,807,000 | $-68,324,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $65,842,000 | $-60,408,000 | $-73,568,000 | $-65,689,000 |
| Cash Flow From Continuing Operating Activities | $65,842,000 | $-60,408,000 | $-73,568,000 | $-65,689,000 |
| Operating Gains Losses | $-10,000 | $888,000 | $541,000 | $603,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-576,000 | $-801,000 | $-1,239,000 | $-2,635,000 |
| Investing Cash Flow | $-105,290,000 | $65,645,000 | $23,763,000 | $-53,664,000 |
| Cash Flow From Continuing Investing Activities | $-105,290,000 | $65,645,000 | $23,763,000 | $-53,664,000 |
| Net Other Investing Changes | $-54,000 | - | $2,000 | $-29,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $111,000 | $43,798,000 | $7,000 | $17,802,000 |
| Financing Cash Flow | $-1,120,000 | $43,250,000 | $-1,346,000 | $40,746,000 |
| Cash Flow From Continuing Financing Activities | $-1,120,000 | $43,250,000 | $-1,346,000 | $40,746,000 |
| Net Other Financing Charges | $-548,000 | - | $-776,000 | $-6,000 |
| Net Common Stock Issuance | $111,000 | $43,798,000 | $-1,000 | $17,802,000 |
| Common Stock Issuance | $111,000 | $43,798,000 | $7,000 | $17,802,000 |
| Repurchase Of Capital Stock | - | - | $-8,000 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-683,000 | $-548,000 | $-569,000 | $-513,000 |
| End Cash Position | $36,275,000 | $78,494,000 | $31,586,000 | $82,216,000 |
| Beginning Cash Position | $78,494,000 | $31,586,000 | $82,216,000 | $160,893,000 |
| Effect Of Exchange Rate Changes | $-1,651,000 | $-1,579,000 | $521,000 | $-70,000 |
| Changes In Cash | $-40,568,000 | $48,487,000 | $-51,151,000 | $-78,607,000 |
| Net Issuance Payments Of Debt | $-683,000 | $-548,000 | $-569,000 | $22,950,000 |
| Net Long Term Debt Issuance | $-683,000 | $-548,000 | $-569,000 | $22,950,000 |
| Long Term Debt Payments | $-683,000 | $-548,000 | $-569,000 | $-513,000 |
| Net Investment Purchase And Sale | $-104,660,000 | $66,446,000 | $25,000,000 | $-51,000,000 |
| Net PPE Purchase And Sale | $-576,000 | $-801,000 | $-1,239,000 | $-2,635,000 |
| Purchase Of PPE | $-576,000 | $-801,000 | $-1,239,000 | $-2,635,000 |
| Interest Received Cfo | $1,563,000 | $595,000 | $69,000 | $0 |
| Interest Paid Cfo | $-129,000 | $-176,000 | $-478,000 | $-473,000 |
| Change In Working Capital | $107,514,000 | $-15,160,000 | $-8,432,000 | $6,841,000 |
| Change In Other Working Capital | $89,478,000 | $-449,000 | $-130,000 | $425,000 |
| Change In Payables And Accrued Expense | $2,350,000 | $1,907,000 | $-7,187,000 | $5,130,000 |
| Change In Accrued Expense | $1,373,000 | $1,137,000 | $-6,114,000 | $5,214,000 |
| Change In Payable | $977,000 | $770,000 | $-1,073,000 | $-84,000 |
| Change In Prepaid Assets | $2,135,000 | $-1,748,000 | $-1,718,000 | $791,000 |
| Change In Receivables | $13,551,000 | $-14,870,000 | $603,000 | $495,000 |
| Changes In Account Receivables | $14,800,000 | $-14,800,000 | $0 | $0 |
| Other Non Cash Items | $188,000 | $1,098,000 | $-204,000 | $-6,196,000 |
| Stock Based Compensation | $5,470,000 | $4,365,000 | $3,330,000 | $4,126,000 |
| Depreciation Amortization Depletion | $2,162,000 | $2,215,000 | $2,359,000 | $2,406,000 |
| Depreciation And Amortization | $2,162,000 | $2,215,000 | $2,359,000 | $2,406,000 |
| Depreciation | $2,162,000 | $2,215,000 | $2,359,000 | $2,406,000 |
| Pension And Employee Benefit Expense | $-10,000 | $888,000 | $541,000 | $590,000 |
| Net Income From Continuing Operations | $-50,916,000 | $-54,233,000 | $-70,753,000 | $-72,996,000 |
| Issuance Of Debt | - | $0 | $0 | $23,463,000 |
| Long Term Debt Issuance | - | $0 | $0 | $23,463,000 |
| Gain Loss On Sale Of PPE | - | $0 | $0 | $13,000 |
| Proceeds From Stock Option Exercised | - | - | $7,000 | $1,082,000 |
| Common Stock Payments | - | - | $-8,000 | $0 |
| Net Short Term Debt Issuance | - | - | $0 | $0 |
| Short Term Debt Payments | - | - | $0 | $0 |
| Sale Of PPE | - | - | $0 | $0 |